Tranexamic Acid vs Hydroquinone for Melasma: Complete Comparison Guide | Korean Plastic Surgery

2 hours ago
4 min read

Tranexamic acid (TXA) and hydroquinone are the two most evidence-supported topical and intradermal treatments for melasma, a chronic hyperpigmentation condition of the cheeks, forehead, and upper lip. Hydroquinone has been the global gold standard for decades, but TXA has moved into mainstream dermatology in 2026, particularly in Korean clinics. This guide compares mechanism, efficacy, side effect profile, formulation options, and when combination therapy is preferred. Use it to ask your dermatologist informed questions before starting either regimen.

How Hydroquinone Works on Melanocytes

Hydroquinone inhibits tyrosinase, the rate-limiting enzyme in melanin synthesis, and reduces melanocyte function over weeks of consistent application. Prescription strengths range from 2% to 4%, with compounded formulas going higher. Hydroquinone delivers fast visible lightening and remains effective on epidermal melasma. The trade-off is cumulative risk: paradoxical hyperpigmentation (exogenous ochronosis) and rebound hyperpigmentation after discontinuation are documented in long-term users, which is why dermatologists typically limit continuous use to 12 to 16 weeks.

How Tranexamic Acid Works for Melasma

Tranexamic acid is a synthetic lysine analog originally developed as an antifibrinolytic. In dermatology, TXA reduces melanogenesis by blocking the plasminogen-plasmin pathway, which downregulates ultraviolet-induced inflammation and tyrosinase activation. Oral TXA, topical 2 to 5% formulations, and intradermal microinjections are the three delivery routes. Korean dermatologists increasingly prefer intradermal TXA for moderate to severe melasma because it bypasses oral systemic exposure and concentrates active drug at the pigment site.

Korean patient considering tranexamic acid versus hydroquinone melasma treatment

Efficacy Head-to-Head: What the 2026 Evidence Shows

A 2026 systematic review and meta-analysis published in Dermatologic Therapy found significant effect favoring TXA in moderate melasma subgroups, though the overall pooled effect did not clearly outperform hydroquinone. Topical and intradermal TXA demonstrated comparable or superior efficacy to hydroquinone with fewer irritant reactions. For severe melasma, the strongest combination therapy data favors TXA plus hydroquinone, which outperforms either monotherapy in pigmentation reduction at 12 weeks.

Side Effect Profile and Long-Term Safety

Hydroquinone side effects include irritation, contact dermatitis, paradoxical hyperpigmentation with long-term use, and exogenous ochronosis at higher concentrations. The US FDA limits over-the-counter hydroquinone, and prescription use should be cycled. TXA topical and intradermal use show favorable tolerability with mild erythema as the most common reaction. Oral TXA carries low but real venous thromboembolism risk and is contraindicated in patients with clotting disorders, pregnancy, or hormonal contraception.

Korean Clinic Protocols: How TXA and HQ Are Combined

Korean dermatology clinics in 2026 commonly run a three-stage protocol. Stage 1 (weeks 1 to 4): triple combination cream (hydroquinone 4% plus retinoid plus low-potency steroid) for rapid lightening. Stage 2 (weeks 5 to 12): switch to topical TXA 3% maintenance with optional in-clinic intradermal TXA every 2 weeks. Stage 3 (maintenance): TXA topical plus broad-spectrum sunscreen, with periodic Pico Laser or Spectra sessions for residual dermal pigment. This sequential approach captures hydroquinone speed while transitioning to TXA long-term safety.

When Lasers Outperform Either Topical

Dermal melasma, post-inflammatory hyperpigmentation, and recalcitrant cases respond best to picosecond laser (Pico) or Q-switched 1064 nm at low fluence in combination with topical maintenance. Aggressive laser protocols can paradoxically worsen melasma, so Korean dermatologists use gentle fluence protocols spaced 4 to 6 weeks apart. Lasers are an adjunct, not a replacement, for topical therapy.

How International Patients Should Plan Treatment

Effective melasma treatment requires 12 to 16 weeks minimum for visible reduction. International patients should plan one initial in-clinic visit for diagnosis and starter prescription, then continue topical therapy at home with telemedicine follow-up. Korean clinics provide multilingual coordination and ship maintenance products internationally. Sun protection is non-negotiable; without daily SPF 50 broad-spectrum, neither TXA nor hydroquinone will hold the result.

Frequently Asked Questions

Is tranexamic acid safer than hydroquinone?

Topical and intradermal TXA show favorable tolerability and avoid the rebound hyperpigmentation risk of long-term hydroquinone. Oral TXA carries a small thrombosis risk. Safety also depends on dose and duration.

Can I use both at the same time?

Yes. Combination therapy outperforms monotherapy in moderate to severe melasma. Korean clinics frequently sequence hydroquinone-led induction with TXA-led maintenance, or layer topical TXA over hydroquinone in the active phase.

How long until I see results?

Hydroquinone shows visible lightening in 4 to 6 weeks. Topical TXA shows reduction at 8 to 12 weeks. Intradermal TXA produces visible change in 4 to 8 weeks. All three require sun protection to maintain results.

Does melasma come back after stopping treatment?

Yes. Melasma is a chronic condition driven by hormonal, ultraviolet, and inflammatory triggers. Stopping treatment leads to gradual recurrence; ongoing maintenance with topical TXA and sunscreen is standard.

Can I get hydroquinone over the counter in Korea?

No. Hydroquinone is prescription only in Korea. International patients can obtain it through Korean dermatology clinics with a valid consultation.

Considering melasma treatment in Korea? Book a dermatology consult, request a sequential TXA plus hydroquinone protocol, and confirm sunscreen and follow-up schedule before traveling.

Sources

Authoritative references: KHIDI (Korea Health Industry Development Institute) · Korean Society of Plastic and Reconstructive Surgeons · PubMed clinical literature. International guidelines from FDA, AAD, and peer-reviewed dermatology journals were consulted where applicable.

Last Medically Reviewed: 2026-05-30

This article was last reviewed for clinical accuracy on May 30, 2026 by the Korean Plastic Surgery editorial team in consultation with international patient program coordinators. Information is general guidance only and does not substitute for in-person consultation with a board-certified physician.